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Edited by Vladimir SkulachevAbstract To understand the role of the superoxide-generating
NADPH oxidase NOX1 in the vascular system, we have gener-
ated NOX1-deﬁcient mice. NOX1-deﬁcient mice had a moder-
ately decreased basal blood pressure. In response to
angiotensin II they showed an almost complete loss of the sus-
tained blood pressure response, while the initial increase was con-
served. NOX1-deﬁcient mice showed a marked reduction in
aortic media hypertrophy. Angiotensin II-induced smooth muscle
cell proliferation was conserved, but there was a marked de-
crease in extracellular matrix accumulation. Our results estab-
lish a role for NOX1 in blood pressure regulation and vascular
angiotensin II response.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Regulation of blood pressure is a vital function in mammals
and both types of blood pressure deregulation, hypotension
and hypertension, are life-threatening. The discovery that the
small inorganic molecule nitric oxide acts as the endothe-
lium-derived vascular relaxation factor was a major break-
through in the understanding of vascular biology (for recent
review see [1]). Over the last decade, it has become clear that
a second group of small inorganic molecules play an important
role in vascular biology, namely reactive oxygen species
(ROS), which mediate vasoconstriction [2–5]. There is now
ample evidence that the activity of hypertensive mediators such
as angiotensin II is at least in part due to ROS generation [6,7].
Several hypotheses concerning the mechanism of ROS-induced
blood pressure elevations have been suggested, including nitric
oxide depletion, direct eﬀects of ROS on smooth muscle con-
traction, and smooth muscle hypertrophy [2].Abbreviations: ROS, reactive oxygen species; ECM, extracellular ma-
trix; SBP, systolic blood pressure; CSMA, cross sectional media area;
PCNA, proliferative cell nuclear antigen
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doi:10.1016/j.febslet.2005.12.049Investigations on the source of ROS generation in the vascu-
lar system have increasingly suggested an important role for
NOX NADPH oxidases [4,8–11]. NOX proteins are a family
of superoxide-generating enzymes. To this date, in mammals
seven members are known: NOX1–5 and DUOX1-2 [8]. Diﬀer-
ent NOX family members show distinct expression patterns in
the vascular system [11,12]: NOX1 is expressed in smooth mus-
cle cells; NOX2 is found in macrophages, adventitial ﬁbro-
blast, and to some extent also in endothelium and smooth
muscle; NOX4 is abundantly expressed in endothelium and
smooth muscle.
Angiotensin II is a key mediator of increased arterial blood
pressure and of vascular disease. Angiotensin II perfusion in
mice has therefore become a valuable model for the under-
standing of hypertension and associated pathologies [13–16].
Key features of angiotensin II-induced vascular alterations in-
clude: (i) sustained blood pressure elevations, (ii) increase in
the thickness of the aortic media through mechanisms includ-
ing smooth muscle proliferation and accumulation of extracel-
lular matrix (ECM) proteins, (iii) markers of inﬂammation
including oxidative damage to the vascular tissue, inﬁltration
of monocytes/macrophages and activation matrix metallopro-
teases, and (iv) induction of atherosclerosis in ApoE-deﬁcient
mice. Angiotensin II signal transduction is complex and in-
volves at least two diﬀerent receptors and the activation of
multiple intracellular signaling pathways [17,18]. There is
now increasing evidence that ROS generation through NOX
enzymes is one of the important signaling pathways in angio-
tensin II signal transduction [4,8–11].2. Materials and methods
2.1. Materials
Sources of antibodies was as follows: goat polyclonal anti-8 hydrox-
yguanosine (Alexis Biochemical); proliferative cell nuclear antigen
(PCNA) monoclonal antibody (DAKO, Switzerland); biotinylated sec-
ondary antibodies from the appropriate species were obtained from
standard suppliers; paraﬃn (Histolab); all other reagents were from
standard suppliers and of highest available grade.2.2. Animals
A targeting vector designed to replace exons III–VI of the NOX1
gene was constructed (Fig. 1A). Probes for Southern blotting (probe
a and b) were chosen outside the ﬂanking sequence of the targeting
vector. For the generation of NOX1-deﬁcient mice, 129SvJ embryonic
stem cells were electroporated with the Not1-linearized targeting
vector construct. G418 resistant clones were analysed by a primaryblished by Elsevier B.V. All rights reserved.
Fig. 1. Generation of NOX1-deﬁcient mice. (A) Overview over the
NOX1 gene locus (upper part) and the knock-out construct (lower
part). Position of Southern blot probes (probe a and b) and restriction
sites are indicated (X = Xmn1; Xba = Xba1). The arrow depicts the
neomycin resistance in the knock-out construct (including additional
Xmn1 and Xba1 sites). (B) Southern blot analysis (probe b) of Xmn1-
digested genomic DNA from F1 animals (#30, #31; #32; #33 carried
the transgene, #29 was wild-type). (C) Southern blot analysis (probe a)
of Xba1-digested genomic DNA from F2 animals (#65, a hemizygous
male and #66 a heterozygous female) and a 129SvJ wild-type control.
(D) Same as panel C, but using a neo probe.
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#3E3 was selected for blastocyst injection. Male chimaeras were mated
to C57BL/6J female mice to obtain the F1 generation. Female F1 ani-
mals were screened for the recombinant allel by PCR followed by
Southern blot veriﬁcation. Four animals #30, #31, #32 and #33 were
identiﬁed to be transgenic (Fig. 1B) and further mated with C57BL/6J
males to generate F2 animals. Fig. 1C and D show a hemizygous F2
knock-out male (note that NOX1 is located on the X-chromosome),
a heterozygous F2 knock-out female, and a wild-type 129SvJ control
using probe A (see Fig. 1A) or a neomycin probe, respectively. Ani-
mals were crossed into a C57BL/6J background, and results shown
in this study were obtained with F6 generation animals. Wild-type con-
trols were either littermates or wild-type C57BL/6J. For our experi-
ments, only males from 12 to 30 weeks of age (weight 25–35 g) were
used. Animals were kept under speciﬁc pathogen free (SPF) conditions
and taken out from the SPF facility in the weeks preceding the exper-
imentation. Genotype controls were realized in each animal used for
experimentation.
All mice were housed in a quiet room at 25 C with a 12-h light/dark
cycle and free access to food and water. The animal procedures de-
scribed in this study were approved by the Ethic committee of Animal
Care in Geneva and Cantonal Veterinary Oﬃce.
2.3. Implantation of minipumps
For implantation of subcutaneous minipump (AZLET model; Co,
Palo Alto, CA, USA), mice were anesthetized with inhaled isoﬂurane
(5% at induction followed by an 2%). Minipumps were implanted
through an incision in the midcapular region under sterile conditions.
Angiotensin II (Sigma, CA, SW) was dissolved in NaCl 0.9% for infu-
sion at 3 mg/kg/day [16]. Sham-treated animals underwent an identical
surgical procedure, except that osmotic minipumps containing NaCl
0.9% were implanted.2.4. Systolic blood pressure (SBP) measurements
SBP was measured in awake mice by tail-cuﬀ plethysmography
(RTBP 200, Kent Scientiﬁc, ADI Instrument, USA) [19]. Baseline mea-
surements were performed at least on three diﬀerent days before the
implantation of minipumps. Animals were considered as well trained
if SBP variability was 640 mmHg, i.e. ±20 mmHg. All reported SBP
values represent an average of at least 10 repeated measurements per
time point and animal.
2.5. Tissue preparations
Mice were sacriﬁced at day 7 after implantation of minipumps. The
thoracic aorta was removed and divided into 2 equal-sized parts; one
part was ﬁxed in formaldehyde (48 h) for histology and immunohisto-
chemistry; the other part was used for mRNA analysis.
2.6. Quantitative image analysis
 For measurements of cross sectional media area (CSMA),
two HE-stained sections per animal, each spaced 20 lm
apart, were digitally photographed at a magniﬁcation of
100· and images were analysed using Metamorph software
(version 6.2r2; Universal Imaging). To delimit the aortic
media, the perimeters of the internal and external elastic
laminas were traced and the area within respective perime-
ters was computed. The data of two sections per animal
were averaged.
 For measurements of cell number per CSMA, digitalized
images of HE-stained sections were used to count the num-
ber of nuclei included within the internal and external elas-
tic laminas.
 To quantify elastic ﬁbers and ECM, we used aldehyde fuch-
sin-stained sections and computed the medial surface area
of the respective colours (purple for elastic ﬁbers; light blue
for ECM) with Metamorph Image Software.
 To measure the number of PCNA-positive nuclei, sections
were screened by light microscopy and PCNA-positive nu-
clei within the media region were directly counted. To dis-
tinguish PCNA-positive nuclei from non-speciﬁc staining,
the samples were focused along the z-axis and only dots
that displayed a clearly deﬁned nuclear shape were counted.
2.7. Histochemistry and immunohistochemistry
For histology and immunohistochemistry, specimen were ﬁxed in
formaldehyde, embedded in paraﬃn, and subsequently sectioned at
5 lm. Hematoxylin eosin, aldehyde fuchsin, and Masson’s trichrome
staining was performed according to standard procedures. For immu-
nohistochemistry, sections were deparaﬃnated and incubated over-
night with the diﬀerent antibodies at the indicated concentrations,
followed by a 2 h incubation with an appropriate biotinylated second-
ary antibody. A peroxidase-based system was used for detection. For
each experiment, controls in the absence of the primary antibody were
performed (data not shown).
2.8. Real time PCR
Thoracic aorta samples were placed in RNA later (Qiagen). RNA
was extracted by RNeasy Protect mini kit (Qiagen, Basel, Switzerland)
and reverse transcribed using the superscript reverse transcriptase
(Superscript Choice; Invitrogen). Reference genes were EEF1A1
(eukaryotic elongation factor 1A1) and TBP (Tata box binding pro-
tein). For PCR primers see supplementary material.
2.9. Statistical analysis
Diﬀerences in blood pressure values were assessed using analysis of
variance (ANOVA) with repeated measure design. For mean compar-
ison of quantitative PCR non-parametric tests were used, due to the
smaller sample size. Bioimaging quantiﬁcations (e.g., diﬀerences in
CSMA, number of nuclei, PCNA-staining) were assessed using a two
way ANOVA with interaction measurement design. All data were
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Analyses were performed with the Stata 8.2, statistical package (Stata
Corporation, College Station, TX 77845, USA).Fig. 2. NOX expression and oxidative stress markers in NOX1-
deﬁcient mice. 3 mg/kg/day angiotensin II (ang II) or physiological
NaCl (sham) were perfused through implanted minipumps for
duration of 7 days; animals were sacriﬁced at day seven and aortic
tissue immediately removed. (A) RT-PCR demonstrated the presence
of NOX1 mRNA in the aorta of wild-type mice (WT), but its absence
in knock-out mice; typical experiment, similar results were obtained
from three independent experiments. (B,C) Real time PCR was
performed to determine mRNA levels of NOX2 and NOX4 (no
signiﬁcant diﬀerences); values normalized with respect to two reference
genes (RG) and shown as means ± S.E. (n = 3–5). (D) Immunohisto-
chemical staining with antibodies against 8-hydroxy guanosine (a
marker of in vivo oxidative stress; dilution 1/200); typical experiment,
similar results were obtained from four independent animals. Scale
bar = 50 lm.3. Results
3.1. NOX1-deﬁcient mice
NOX1-deﬁcient mice were generated as described in Section
2 and in Fig. 1. NOX1-deﬁcient mice were healthy, reproduced
normally and did not show a spontaneous phenotype. In this
manuscript, we describe eﬀects of NOX1 deﬁciency on blood
pressure and vascular responses to angiotensin II. For the
experiments shown here, only mice with at least 6 generations
of backcross into a C57BL/6J background were used.
To document that NOX1 was indeed absent from the vascu-
lar system, we took aorta from control and from knock-out
mice and performed RT-PCR with NOX1-speciﬁc primers
(Fig. 2A). Thus, NOX1 mRNA was indeed absent from the
aorta of our knock-out mice. To investigate the possibility that
there is a compensatory upregulation of other NOX family
members in NOX1-deﬁcient mice, we have performed real time
PCR for NOX2 and NOX4 in the aorta of sham- and angio-
tensin II-treated mice (Fig. 2A and C). There were no major
changes in the levels of NOX4. There was a 4-fold angiotensin
II-induced increase of NOX2 in NOX1-deﬁcient mice com-
pared with a 2-fold angiotensin II-induced increase in WT,
however this diﬀerence was not statistically signiﬁcant.
As an indicator of oxidative stress in vivo, we used antibod-
ies against 8-hydroxy guanosine (Fig. 2D, [20]). In sham-trea-
ted mice, there was a moderate labelling in the endothelial and
the adventitial layer, but only a weak staining in the media. In
angiotensin II-treated wild-type mice, the media was strongly
stained. Thus, we conclude that angiotensin II leads to an in-
crease in ROS generation in the aortic media. In contrast to
wild-type mice, angiotensin II led to no, or only a minor, in-
crease of 8-hydroxy guanosine staining in the media of
NOX1-deﬁcient mice. This demonstrates that NOX1 is a ma-
jor of source of ROS in angiotensin II-stimulated aortic media.
In summary, the results shown in Fig. 2 demonstrate that we
have generated knock-out mice which did not express NOX1
mRNA. In the aorta of these mice, there was no major com-
pensatory upregulation of other NOX family members, but a
marked decrease in angiotensin II-induced oxidative stress.
3.2. Nox1-deﬁcient mice present a decreased systolic blood
pressure in response to angiotensin II
Basal SBP was 116 ± 12 mmHg in control and 108 ±
15 mmHg in NOX1-deﬁcient mice (means ± S.D.; n = 25; 4 se-
rial measurements per mouse; P = 0.03). This suggests a role
for NOX1 in blood pressure regulation. We therefore investi-
gated the eﬀect of angiotensin II. For this purpose, mice were
perfused with angiotension II (3 mg/kg per day) over a 7 day
period (Fig. 3). Over the ﬁrst 3 days, angiotensin II led to an
increased SBP in the both groups of mice, while sham-treated
controls showed only baseline variations. However, at day 6,
there was a persistent increase in SBP in wild-type mice, while
SBP of NOX1-deﬁcient mice was close to baseline values. The
diﬀerence in blood pressure between wild-type and knock-out
on day 6 after angiotensin II perfusion was highly signiﬁcant
(Fig. 3C). Thus, we conclude that NOX1 is required for sus-
tained SBP elevations in response to angiotensin II.Increased loss of intravascular volume might be a plausible
mechanism for the absence of a prolonged SBP response in
NOX1-deﬁcient mice. However, weight measurements
(Fig. 3D) excluded such an hypothesis, as angiotensin II-in-
duced weight loss was comparable in control and knock-out
mice.
3.3. Nox1 deﬁciency decreases angiotensin II-induced media
hypertrophy, but not cell proliferation
Media hypertrophy is a hallmark of prolonged angiotensin
II application in mice [21,22]. We therefore measured the cross
sectional media area, CSMA, in hematoxylin eosin (HE)-
Fig. 3. NOX1 is required for prolonged blood pressure elevations in response to angiotensin II. Mice were treated with angiotensin II (ang II) as
described in Fig. 1 and systolic blood pressure, SBP, was measured using tail cuﬀ plethysmography. Days of measurement are indicated with respect
to pump implantation; day 0 = basal systolic blood pressure before pump implantation. (A,B) SBP changes in angiotensin II- or sham-treated wild-
type (WT) and NOX1-deﬁcient (KO) mice. (C) Comparison of SBP after angiotensin II treatment in wild-type and NOX1-deﬁcient mice. (D) Body
weight before (d0) and 7 days after (d7) ang II or sham treatment of wild-type and NOX1-deﬁcient mice. n = 26 and n = 25, for wild-type and for
knock-out animals, respectively. Data are shown as means ± S.E. \P < 0.05; \\\P < 0.0001 for the comparison of wild-type with knock-out animals.
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mals, the CSMA was similar in wild-type and in NOX1-deﬁ-
cient animals. In contrast, in response to angiotensin II,
wild-type animals increased their CSMA by 26only by 14%
(P < 0.05). Thus, NOX1 deﬁciency attenuated the increase in
media diameter in response to angiotensin II, demonstrating
a role for NOX1 in angiotensin-induced media hypertrophy.
A role for NOX1 in vascular smooth muscle cell prolifera-
tion has been proposed [23]. We have therefore counted the
number of nuclei (i.e., cells) in the media in aortic cross sec-
tions (Fig. 4C). In both, wild-type and NOX1-deﬁcient ani-
mals, the number of cells in the media is signiﬁcantly
increased in response to angiotensin II. The increase is slightly
lower in NOX1-deﬁcient animals, but the diﬀerence between
wild-type and knock-out was not statistically signiﬁcant
(P = 0.49). Thus, the angiotensin II-induced increase in media
thickness, but not cell number depends on the presence of
NOX1.
To further investigate this point, we have investigated the
expression of proliferative cell nuclear antigen, PCNA, a widely
used marker of cell proliferation (Fig. 5A, see for example
Ref. [24]). In the absence of angiotensin II treatment, the num-
ber of proliferating PCNA-positive cells was low. After angio-tensin II treatment, both, wild-type and knock-out mice
showed a comparable increase in PCNA-positive cells. Quanti-
tative analysis of the percentage of PCNA-positive cells re-
vealed no diﬀerences between NOX1-deﬁcient and wild-type
animals (Fig. 5B). Thus, decreased smooth muscle cell prolifer-
ation is not the mechanism explaining the decreased media
hypertrophy in NOX1-deﬁcient mice.
3.4. Decreased extracellular matrix accumulation in NOX1-
deﬁcient mice
An increase in ECM proteins in the aortic media in response
to angiotensin II is well established [25]. We therefore per-
formed aldehyde fuchsin and Masson’s trichrome staining of
aortic sections (Fig. 6A). Aldehyde fuchsin staining allows to
visualize elastic ﬁbers (purple) and ECM proteins (light blue),
while Masson’s trichrome staining allows to visualize cyto-
plasm of cells (red) and ECM proteins (blue). Visual inspection
of the aldehyde fuchsin stained sections revealed an increased
distance between elastic ﬁbers in response to angiotensin II
treatment in aortas from wild-type mice (Fig. 6A, middle pan-
els). This increase in distance between elastic ﬁbers was mark-
edly attenuated in knock-out mice. Visual inspection of the
Masson’s trichrome stainings revealed no diﬀerences between
Fig. 4. NOX1 is involved in angiotensin II-induced media hypertrophy. Mice were treated with angiotensin II (ang II) as described in Fig. 1 and
sacriﬁced at day 7. (A) Aortic sections were stained by hematoxylin/eosin; typical experiment. (B) Cross sectional media area (CSMA) in aortic
section was determined by quantitative bioimaging as described in Section 2 (means ± S.E, n = 14 for ang II treated animals, and n = 9 for sham
treated mice). (C) Number of nuclei per CSMA (means ± S.E., n = 14 for angiotensin II treated animals, and n = 9 for sham treated mice). (D)
Comparison of angiotensin II-induced increase in CSMA and increase in numbers of nuclei per CSMA in wild-type and NOX1-deﬁcient animals
(increase in wild-type mice = 100%). \P < 0.05 for the comparison of wild-type with knock-out animals. Scale bar = 50 lm.
Fig. 5. NOX1 is not required for the induction of aortic smooth muscle proliferation by angiotensin II. Mice were treated with angiotensin II (ang II)
as described in Fig. 1 and sacriﬁced at day 7. (A) Immunohistochemical staining of aortic sections using antibodies against PCNA (proliferating cell
nuclear antigen; antibody dilution 1/100); typical experiment, similar results were obtained from 4 separate animals. (B) PCNA stained sections were
quantitatively analysed for PCNA-positive nuclei (means ± S.E., 12 determinations of 4 separate animals). Scale bar = 50 lm.
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However, while abundant patches of blue ECM proteins were
found in the aortic media of angiotensin II-treated wild-type
mice, in NOX1-deﬁcient mice ECM proteins are mainly seen
as ﬁne lining along the elastic ﬁbers (Fig. 6A, right panels),
similar as observed with sham-treated mice. To quantify therelative amount of elastic ﬁbers and ECM proteins, we per-
formed image analysis of the aldehyde fuchsin-stained sec-
tions. We did not observe any changes in the area occupied
by elastic ﬁbers (Fig. 6B). As expected, the ECM area in-
creased in wild-type mice in response to angiotensin II. This in-
crease was markedly attenuated in NOX1-deﬁcient mice
Fig. 6. Angiotensin II-induced ECM accumulation is diminished in NOX1-deﬁcient mice. Mice were treated with angiotensin II (ang II) as described
in Fig. 1 and sacriﬁced at day 7. (A) Aortic sections were stained with aldehyde/fuchsin (AF; elastic ﬁbers are purple and ECM light blue) or
trichrome/Masson (TCM, cells are red and ECM blue); typical experiments, similar results were obtained from 4 separate animals. (B,C) Surface area
of elastic ﬁbers (EF) and ECM was quantiﬁed as described in Section 2 (means ± S.E, n = 14 for ang II treated animals, and n = 9 for sham treated
mice). \P < 0.05 for the comparison of wild-type with knock-out animals. Scale bar = 50 lm.
502 G. Gavazzi et al. / FEBS Letters 580 (2006) 497–504(Fig. 6C). Thus, we conclude that NOX1 is involved in the
mediation of angiotensin II-induced ECM accumulation in
the aortic media.4. Discussion
An involvement of NOX family NADPH oxidases in the reg-
ulation of blood pressure is now generally accepted. However,
the question of which among the family members are most
important and how they exert their action remained open. A
role for the phagocyte NADPH oxidase subunit p47phox is well
established: vascular smooth muscle cells from p47phox-deﬁ-
cient mice do not produce superoxide [26] and blood pressure
is decreased in these animals [27]. However, the role of the
NOX2/gp91phox is less clear. Indeed, while NOX2 appears to
be expressed in vascular smooth muscle cells from resistance
arteries [28], it is absent or expressed only at very low levels
in smooth muscle cells from large arteries [29,30]. Blood pres-
sure measurements in NOX2/gp91phox-deﬁcient mice showed
a moderate decrease (from 142 to 126 mmHg) in angiotensin
II-treated animals in one study [16], while in another study
angiotensin II-dependent chronic hypertension was unaﬀected
by NOX2/gp91phox-deﬁciency [31]. The focus has thereforeturned on other NOX isoforms that might play a role in the
stimulated ROS generation in smooth muscle of large arteries.
NOX4 is thought to play a role in basal ROS generation by
smooth muscle cells [32], but is unlikely candidate for stimu-
lated ROS release, as it is independent of cytoplasmic subunits,
in particular p47phox [33]. NOX3 appears to be relatively spe-
ciﬁc for the inner ear [34], while NOX5 is not found in rodents
(unpublished data). Thus attention rests on NOX1. In the ab-
sence of a NOX1-deﬁcient mouse, evidence remained circum-
stantial, however several arguments pointed towards a
possible role of NOX1: (i) NOX1 is expressed in the smooth
muscle of large arteries [35,36]; (ii) it is upregulated and stimu-
lated in response to angiotensin II [35,37,38], (iii) anti-sense
suppression of NOX1 in these cells leads to a inhibited stimu-
lated ROS generation [35], and (iv) p47phox may act as orga-
nizer subunit of NOX1 (e.g. [39]). Our results provide a proof
of principle: angiotensin II-induced blood pressure elevations
strongly depend on NOX1. However, our data also introduces
a complexity that had received little attention before. Indeed,
most studies investigating the role of NOX enzymes in blood
pressure regulation measured a single time point (in general
after 7 days of angiotensin II infusion). Our observations sug-
gest that only the sustained blood pressure elevations in re-
sponse to angiotensin II depend on NOX1. In contrast, blood
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largely NOX1-independent. It remains to be investigated
whether these early angiotensin II responses are NOX/ROS-
independent or whether they are mediated by NOX enzymes
other than NOX1. It will also be of interest to investigate to
which extent other hypertensive agents, such as a-
adrenergic agonists, use NOX1-dependent or -independent
pathways.
At least three mechanisms are thought to contribute to the
increased media thickness in response to angiotensin II: cell
proliferation, cellular hypertrophy (i.e., increased cell vol-
ume), and increase in extracellular matrix [13]. In vitro data
suggest that NOX1 is involved in smooth muscle cell prolif-
eration, an observation which also led to the initial designa-
tion of the enzyme as mox-1, i.e., mitogenic oxidase 1 [23].
Our in vivo data suggest that, in response to angiotensin II,
NOX1 does not, or at best in a minor way, contribute to
smooth muscle cell proliferation. We have not investigated
the question whether NOX1 deﬁciency has an inﬂuence on
the size of smooth muscle cells. Our data however clearly
suggest a role of NOX1 in the third pathway towards media
hypertrophy, namely accumulation of ECM. The interaction
of the extracellular matrix with elastic ﬁbers and smooth
muscle is thought to determine aortic stiﬀness [40]. Recent
concepts in blood pressure research suggest that systolic
hypertension is predominantly a function of the stiﬀness of
large arteries [41]. Thus, our observation that NOX1 con-
tributes to the angiotensin II-induced ECM increase in the
aorta might be a relevant aspect of the NOX1-mediated
blood pressure increase.
While we were ﬁnalizing the preparation of this manuscript, a
study by Matsuno et al. describing a decreased blood pressure
response to angiotensin II in NOX1-deﬁcient mice appeared
[42]. Two apparent discrepancies between the two studies
should be noted: (i) we found an eﬀect of NOX1 deﬁciency
on basal blood pressure, while Matsuno et al. did not, and
(ii) we found that the angiotensin II-induced media hypertro-
phy depended partially of NOX1, while Matsuno et al. de-
scribed a preservation of media hypertrophy in NOX1-
deﬁcient animals. It is possible that the small sample size in
the study of Matsuno et al. precluded the detection of these dif-
ferences. Alternative explanations for the discrepancies include
the age of the animals (12–30 weeks in our study, as compared
to 8–12 weeks in Matsuno et al.), and, at least with respect to
media hypertrophy, the angiotensin II doses (3 mg/kg/day in
our study, but 0.7 mg/kg/day in Matsuno et al.). Thus, it is pos-
sible that NOX1 contributes to media hypertrophy only in re-
sponse to high angiotensin II concentrations.
Acknowledgements: The authors thank Angelo Gradia for skilled tech-
nical assistance, the Drs. Didier Cholet, Ce´line Delucinge, Myle`ne
Docquier et Patrick Descombes from the Genomics Platform, NCCR
Frontiers in Genetics (Swiss National Science Foundation). This work
was supported by grants from the Swiss National Science Foundation
(3100A0-103725) and the Louis Jeantet Foundation in Geneva.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2005.
12.049.References
[1] Ganz, P. and Vita, J.A. (2003) Testing endothelial vasomotor
function: nitric oxide, a multipotent molecule. Circulation 108,
2049–2053.
[2] Lassegue, B. and Griendling, K.K. (2004) Reactive oxygen species
in hypertension; an update. Am. J. Hypertens. 17, 852–860.
[3] de Champlain, J., Wu, R., Girouard, H., Karas, M., El Midaoui,
A., Laplante, M. and Wu, L. (2004) Oxidative stress in hyper-
tension. Clin. Exp. Hypertens. 26, 593–601.
[4] Mueller, C.F., Laude, K., McNally, J.S. and Harrison, D.G.
(2005) ATVB in focus: redox mechanisms in blood vessels.
Arterioscler. Thromb. Vasc. Biol. 25, 274–278, Epub. 2004 Oct
28.
[5] Schulman, I.H., Zhou, M.S. and Raij, L. (2005) Nitric oxide,
angiotensin II, and reactive oxygen species in hypertension and
atherogenesis. Curr. Hypertens. Rep. 7, 61–67.
[6] Touyz, R.M., Tabet, F. and Schiﬀrin, E.L. (2003) Redox-
dependent signalling by angiotensin II and vascular remodelling
in hypertension. Clin. Exp. Pharmacol. Physiol. 30, 860–
866.
[7] Zalba, G., San Jose, G., Moreno, M.U., Fortuno, M.A., Fortuno,
A., Beaumont, F.J. and Diez, J. (2001) Oxidative stress in arterial
hypertension: role of NAD(P)H oxidase. Hypertension 38, 1395–
1399.
[8] Lambeth, J.D. (2004) NOX enzymes and the biology of reactive
oxygen. Nat. Rev. Immunol. 4, 181–189.
[9] Griendling, K.K. (2004) Novel NAD(P)H oxidases in the
cardiovascular system. Heart 90, 491–493.
[10] Ray, R. and Shah, A.M. (2005) NADPH oxidase and endothelial
cell function. Clin. Sci. (Lond) 109, 217–226.
[11] Bengtsson, S.H., Gulluyan, L.M., Dusting, G.J. and Drummond,
G.R. (2003) Novel isoforms of NADPH oxidase in vascular
physiology and pathophysiology. Clin. Exp. Pharmacol. Physiol.
30, 849–854.
[12] Rey, F.E. and Pagano, P.J. (2002) The reactive adventitia:
ﬁbroblast oxidase in vascular function. Arterioscler. Thromb.
Vasc. Biol. 22, 1962–1971.
[13] Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., Suzuki,
Y., Mezzano, S., Plaza, J.J. and Egido, J. (2001) Role of the
renin–angiotensin system in vascular diseases: expanding the ﬁeld.
Hypertension 38, 1382–1387.
[14] Kon, V. and Jabs, K. (2004) Angiotensin in atherosclerosis. Curr.
Opin. Nephrol. Hypertens. 13, 291–297.
[15] Daugherty, A. and Cassis, L. (2004) Angiotensin II-mediated
development of vascular diseases. Trends Cardiovasc. Med. 14,
117–120.
[16] Wang, H.D., Xu, S., Johns, D.G., Du, Y., Quinn, M.T., Cayatte,
A.J. and Cohen, R.A. (2001) Role of NADPH oxidase in the
vascular hypertrophic and oxidative stress response to angiotensin
II in mice. Circ. Res. 88, 947–953.
[17] Saito, Y. and Berk, B.C. (2002) Angiotensin II-mediated
signal transduction pathways. Curr. Hypertens. Rep. 4, 167–
171.
[18] Dinh, D.T., Frauman, A.G., Johnston, C.I. and Fabiani, M.E.
(2001) Angiotensin receptors: distribution, signalling and func-
tion. Clin. Sci. (Lond) 100, 481–492.
[19] Johns, C., Gavras, I., Handy, D.E., Salomao, A. and Gavras, H.
(1996) Models of experimental hypertension in mice. Hyperten-
sion 28, 1064–1069.
[20] Tanito, M. et al. (2004) Enhanced oxidative stress and impaired
thioredoxin expression in spontaneously hypertensive rats. Anti-
oxid. Redox Signal 6, 89–97.
[21] Griﬃn, S.A., Brown, W.C., MacPherson, F., McGrath, J.C.,
Wilson, V.G., Korsgaard, N., Mulvany, M.J. and Lever,
A.F. (1991) Angiotensin II causes vascular hypertrophy in
part by a non-suppressor mechanism. Hypertension 17, 626–
635.
[22] Simon, G. (2004) Pathogenesis of structural vascular changes in
hypertension. J. Hypertens. 22, 3–10.
[23] Suh, Y.A. et al. (1999) Cell transformation by the superoxide-
generating oxidase Mox1. Nature 401, 79–82.
[24] Tulis, D.A., Mnjoyan, Z.H., Schiesser, R.L., Shelat, H.S., Evans,
A.J., Zoldhelyi, P. and Fujise, K. (2003) Adenoviral gene transfer
of fortilin attenuates neointima formation through suppression of
504 G. Gavazzi et al. / FEBS Letters 580 (2006) 497–504vascular smooth muscle cell proliferation and migration. Circu-
lation 107, 98–105.
[25] Intengan, H.D. and Schiﬀrin, E.L. (2001) Vascular remodeling in
hypertension: roles of apoptosis, inﬂammation, and ﬁbrosis.
Hypertension 38, 581–587.
[26] Lavigne, M.C., Malech, H.L., Holland, S.M. and Leto, T.L.
(2001) Genetic demonstration of p47phox-dependent superoxide
anion production in murine vascular smooth muscle cells.
Circulation 104, 79–84.
[27] Landmesser, U., Cai, H., Dikalov, S., McCann, L., Hwang, J., Jo,
H., Holland, S.M. and Harrison, D.G. (2002) Role of p47(phox)
in vascular oxidative stress and hypertension caused by angio-
tensin II. Hypertension 40, 511–515.
[28] Touyz, R.M., Chen, X., Tabet, F., Yao, G., He, G., Quinn,
M.T., Pagano, P.J. and Schiﬀrin, E.L. (2002) Expression of
a functionally active gp91phox-containing neutrophil-type
NAD(P)H oxidase in smooth muscle cells from human
resistance arteries: regulation by angiotensin II. Circ. Res.
90, 1205–1213.
[29] Ushio-Fukai, M., Zafari, A.M., Fukui, T., Ishizaka, N. and
Griendling, K.K. (1996) p22phox is a critical component of the
superoxide-generating NADH/NADPH oxidase system and reg-
ulates angiotensin II-induced hypertrophy in vascular smooth
muscle cells. J. Biol. Chem. 271, 23317–23321.
[30] Sorescu, D. et al. (2002) Superoxide production and expression of
nox family proteins in human atherosclerosis. Circulation 105,
1429–1435.
[31] Touyz, R.M. et al. (2005) Angiotensin II-dependent chronic
hypertension and cardiac hypertrophy are unaﬀected by
gp91phox-containing NADPH oxidase. Hypertension 45, 530–
537, Epub. 2005 Mar 7.
[32] Ellmark, S.H., Dusting, G.J., Fui, M.N., Guzzo-Pernell, N. and
Drummond, G.R. (2005) The contribution of Nox4 to NADPH
oxidase activity in mouse vascular smooth muscle. Cardiovasc.
Res. 65, 495–504.[33] Martyn, K.D., Frederick, L.M., von Loehneysen, K., Dinauer,
M.C. and Knaus, U.G. (2005) Functional analysis of Nox4
reveals unique characteristics compared to other NADPH
oxidases. Cell Signal 28, 28.
[34] Banﬁ, B., Malgrange, B., Knisz, J., Steger, K., Dubois-Dauphin,
M. and Krause, K.H. (2004) NOX3, a superoxide-generating
NADPH oxidase of the inner ear. J. Biol. Chem. 279, 46065–
46072, Epub. 2004 Aug 23.
[35] Lassegue, B. et al. (2001) Novel gp91(phox) homologues in
vascular smooth muscle cells: nox1 mediates angiotensin II-
induced superoxide formation and redox-sensitive signaling
pathways. Circ. Res. 88, 888–894.
[36] Lassegue, B. and Clempus, R.E. (2003) Vascular
NAD(P)H oxidases: speciﬁc features, expression, and
regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol.
285, R277–R297.
[37] Wingler, K., Wunsch, S., Kreutz, R., Rothermund, L., Paul, M.
and Schmidt, H.H. (2001) Upregulation of the vascular
NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin–
angiotensin system in vitro and in vivo. Free Radic. Biol. Med.
31, 1456–1464.
[38] Mollnau, H. et al. (2002) Eﬀects of angiotensin II infusion on the
expression and function of NAD(P)H oxidase and components of
nitric oxide/cGMP signaling. Circ. Res. 90, E58–E65.
[39] Banﬁ, B., Clark, R.A., Steger, K. and Krause, K.H. (2003) Two
novel proteins activate superoxide generation by the NADPH
oxidase NOX1. J. Biol. Chem. 278, 3510–3513.
[40] Laurent, S., Boutouyrie, P. and Lacolley, P. (2005) Structural and
genetic bases of arterial stiﬀness. Hypertension 45, 1050–1055,
Epub. 2005 Apr 25.
[41] Izzo Jr., J.L. (2004) Arterial stiﬀness and the systolic hypertension
syndrome. Curr. Opin. Cardiol. 19, 341–352.
[42] Matsuno, K. et al. (2005) Nox1 is involved in angiotensin II-
mediated hypertension: a study in Nox1-deﬁcient mice. Circula-
tion 112, 2677–2685.
